Phase 2 clinical trial recently expanded to include adolescents following independent review of early safety dataFirst adolescent patient with EB enrolled into clinical trial and completed treatment...
BERKELEY, Calif.--(BUSINESS WIRE)--Lygos, Inc., a vertically integrated provider of safe and sustainable specialty ingredients, today announced that it has successfully completed commercial-scale, fermentation-based production campaigns for its Lygos CBx cannabinoid products, including CBG (cannabigerol), CBC (cannabichromene), CBD (cannabidiol), and CBDA (cannabidiolic acid). These campaigns validate the company’s ability to produce a variety of high-quality cannabinoids and cannabinoid-based products for a growing number of recreational, health & wellness, and pharmaceutical applications, all in an environmentally safe, sustainable, and cost-effective manner.
VANCOUVER, British Columbia, July 14, 2021 (GLOBE NEWSWIRE) -- Christina Lake Cannabis Corp. (the “Company” or “CLC” or “Christina Lake Cannabis”) (CSE: CLC) (OTCQB: CLCFF) (FRANKFURT: CLB) is pleased to provide its first operational update pertaining to the 2021 growing season in which the Company is cultivating a large quantity of clones and seedlings outdoors under natural sunlight. In addition to the seven proprietary cannabis strains which comprise the majority of CLC’s plants being grown this year, more than 90 experimental strains are also under observation in the field with an objective of identifying certain favourable characteristics (e.g., resistance to mould and pests, tolerance of natural outdoor elements). As demand persists for distillate oils containing high concentrations of tetrahydrocannabinol (“THC”), this attribute is specifically prioritized by CLC’s Master Growers when assessing experimental cannabis strains to be used for extraction.
VANCOUVER, British Columbia, July 06, 2021 (GLOBE NEWSWIRE) -- Cannabix Technologies Inc. (CSE: BLO) (OTC PINK: BLOZF) (the “Company” or “Cannabix”) developer of the Cannabix Marijuana Breathalyzer devices for law enforcement and the workplace, announces that the Canadian Intellectual Property Office (CIPO) has granted patent No. 2887841 entitled, “Cannabis Drug Detection Device”. The Company has been pursuing this original patent application since its filing on April 16, 2015. Cannabix Technologies is on the forefront in research and development to create point-of-care breath testing technologies for the detection of ?9-tetrahydrocannabinol (“THC”) - the psychoactive component of marijuana that causes impairment.
VANCOUVER, British Columbia, June 29, 2021 (GLOBE NEWSWIRE) -- Christina Lake Cannabis Corp. (the “Company” or “CLC” or “Christina Lake Cannabis”) (CSE: CLC) (OTCQB: CLCFF) (FRANKFURT: CLB) is pleased to announce that it has succeeded in its efforts to consistently produce cannabis distillate oils with a tetrahydrocannabinol (“THC”) concentration of 90% or higher, a benchmark that is considered to be highly prestigious in the vaping industry. Based on 2020 data from Health Canada, approximately 37% of Canadian cannabis consumers were users of vape pens, e-cigarettes, and vapourizers1. With the introduction of “Cannabis 2.0” in early 2020 (allowing the production of beverages, edibles, and other everyday products with cannabis), several new categories of cannabis products had emerged from which there was new demand for extracts such as distillate oils. A certificate of analysis dated June 17, 2021 has confirmed that CLC’s distillate oils consistently contain a THC concentration of 90.4%, which is a very critical component for licensed producers who seek to make products containing THC.